

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
14 April 2022 (14.04.2022)



(10) International Publication Number
WO 2022/076289 A1

- (51) International Patent Classification:
A61P 11/06 (2006.01) *C07K 16/28* (2006.01)
- (21) International Application Number:
PCT/US2021/053328
- (22) International Filing Date:
04 October 2021 (04.10.2021)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
63/087,668 05 October 2020 (05.10.2020) US
63/109,719 04 November 2020 (04.11.2020) US
63/144,048 01 February 2021 (01.02.2021) US
63/157,922 08 March 2021 (08.03.2021) US
21315151.7 31 August 2021 (31.08.2021) EP
- (71) Applicants: **SANOBI BIOTECHNOLOGY** [FR/FR]; 54, rue La Boétie, 75008 Paris (FR). **REGENERON PHARMACEUTICALS, INC.**, [US/US]; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US).
- (72) Inventors: **XU, Christine**; c/o Sanofi, 55 Corporate Drive, Mail-Code 55A-505A, Bridgewater, New Jersey 08807 (US). **AKINLADE, Bolanle**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New

York 10591 (US). **AMIN, Nikhil**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **RUDDY, Marcella**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US).

(74) Agent: **STONE-HULSLANDER, Judith** et al.; Lathrop GPM LLP, 28 State Street, Boston, Massachusetts 02109 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: METHODS FOR TREATING ASTHMA IN PEDIATRIC SUBJECTS BY ADMINISTERING AN IL-4R ANTAGONIST




FIG. 1

(57) Abstract: Methods for treating or preventing asthma in a pediatric subject are provided. Methods comprising administering to a pediatric subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof, are provided.

[Continued on next page]

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*